Drug intelligence / Profile preview

polydeoxyribonucleotide

Development stage
Unknown
Lead developer
Hallym University Chuncheon Sacred Heart Hospital
Administration
Intramuscular, Subcutaneous
01

Overview

Polydeoxyribonucleotide (PDRN) is a biologic tissue regeneration activator composed of a mixture of low-molecular-weight deoxyribonucleotide polymers, typically ranging from 50 to 2000 base pairs in length. Derived primarily from the sperm of salmon or trout through a high-temperature sterilization and purification process, PDRN acts as a selective agonist for the adenosine A2A receptor. This activation triggers a cascade of physiological responses, including the stimulation of vascular endothelial growth factor (VEGF) expression and the enhancement of fibroblast activity, which promotes collagen synthesis and angiogenesis. In clinical practice, PDRN is utilized as an injectable therapy for musculoskeletal conditions such as lateral epicondylitis (tennis elbow), where it is often evaluated for its synergistic effects when combined with exercise and extracorporeal shockwave therapy (ESWT) to reduce pain and improve functional outcomes.

Brand names
PlacentexRejuranRe-An
Other names
PDRNpolydeoxyribonucleotide injectiondeoxyribonucleotide polymers
02

Targets

ADORA2A (Adenosine A₂A Receptor)

Beyond the preview

Go deeper on polydeoxyribonucleotide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on polydeoxyribonucleotide.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call